Inve US ▾
HSHSIC

Henry Schein (HSIC) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 5, 2026

Source: earnings call transcript

Executive summary

Henry Schein Q1 FY26 — Strong Start with Market Share Gains and Margin Expansion

Henry Schein delivered strong Q1 FY26 results, driven by market share gains in U.S. dental and robust growth in global technology, despite softness in medical due to a light flu season. The company is focused on operational execution and value creation initiatives, targeting significant operating income improvement and high single-digit to low double-digit earnings growth in the coming years. Management remains confident in its full-year 2026 financial guidance.

Highlights

5
  • Global sales grew 6.3% YoY to $3.4 billion, with local currency internal sales growth of 2.5%.

  • Non-GAAP operating margin expanded by 28 basis points YoY to 7.53%.

  • Adjusted EBITDA grew 11.6% YoY to $289 million.

  • High-growth, high-margin businesses are approaching 50% of total operating income, on track for 2027 goal.

  • U.S. dental merchandise sales grew 5.6% (4.1% internal sales growth), reflecting market share gains.

Concerns

3
  • Medical business impacted by lower demand for point-of-care diagnostic test products due to a light flu season.

  • Digital equipment sales were essentially flat due to continued softness in Interroll scanners and treat printers, driven by lower average selling prices from new market entrants.

  • Value implant sales growth (high single-digit) resulted in lower gross margin for the Global Specialty Products Group compared to prior year due to mix shift.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Total sales growth
approximately 3% to 5% over 2025
high materiality
High
Full-year 2026 Non-GAAP diluted EPS
$5.23 to $5.37
high materiality
High
Full-year 2026 Non-GAAP effective tax rate
approximately 24%
medium materiality
High
Full-year 2026 Adjusted EBITDA growth
mid-single digits
high materiality
High
Full-year 2026 Remeasurement gains
less than recognized in 2025
low materiality
Medium
Annual operating income improvement
greater than $200 million
high materiality
High
Annual operating income improvement run rate
$125 million
high materiality
High
High-growth, high-margin businesses operating income contribution
exceed our goal of 50%
medium materiality
High
Earnings growth
high single-digit to low double-digit
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Global Distribution and Value-Added Services
Strong momentum in the U.S. U.S. dental merchandise sales saw market share gains and price increases. U.S. dental equipment growth was driven by traditional equipment sales, with DSOs investing. U.S. medical sales were impacted by lower point-of-care diagnostic test product demand due to a light flu season, but Home Solutions and dialysis showed strong growth. International dental merchandise growth was strong in the U.K., Italy, and Brazil. International dental equipment growth was good in Germany, U.K., Canada, Australia, and New Zealand.
U.S. dental merchandise sales growth: 5.6% (4.1% internal sales growth)U.S. dental equipment sales growth: 3.4%U.S. medical distribution sales growth: 1.3% (1.2% internal sales growth)International dental merchandise sales growth: 12.5% (1.8% LCI sales growth)International dental equipment sales growth: 13.4% (3.6% LCI sales growth)Global value-added services sales growth: 10.6% (7.8% LCI sales growth)
—6.1%——
Global Specialty Products Group
Implant sales were driven by value implant systems, leading to a lower gross margin due to mix shift. Improved growth is expected for the segment going forward.
Implant sales growth: high single-digit (value implant systems)
—8.1%—lower gross margin compared to the prior year
Global Technology Group
Continued solid results with strong revenue growth in Dentrix Ascend in the U.S. and Dentally internationally. Cloud-based customer base increased significantly.
Cloud-based customers: >13,000 (25% YoY increase)Dentrix Ascend practice management software revenue growth: strongDentally cloud-based practice management software sales growth: driven by new accounts
—7.0%——

HSIC operating KPIs by quarter

HSIC operating KPIs stated on its earnings calls, by fiscal quarter
KPI Dec 2025 Q4 FY25This call Mar 2026 Q1 FY26 Jun 2026 Q2 FY26Change vs prior quarter
Dentrix Ascend and Dentally subscribers
11K+ And now we have more than 11,000 Dentrix Ascend and Dentally subscribers, of course, the largest installed base in the world. Source: earnings call transcript
13K+ The number of cloud-based customers increased by roughly 25% year-over-year, primarily from new accounts, and we now have more than 13,000 Dentrix Ascend and Dentale subscribers. Source: earnings call transcript
<13K Almost 13,000 customers now subscribe to our Dentrix Ascend and Dentale cloud-based platforms, and we're seeing more customers move toward our higher-featured packages, which is increasing our monthly revenue per customer. Source: earnings call transcript
—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
Next-generation AI clinical workflowlaunch

Deals & partnerships

S.I.N. 360 Gained controlling interest in S.I.N. 360, the U.S. distributor of S.I.N. Brazil's value implant systems.

Provides greater control over U.S. implant product portfolio, especially in the faster-growing value implant market, and allows for unlocking growth and back-office integration efficiencies.

Risks & headwinds

Softness in the medical business due to lower demand for point-of-care diagnostic test products Q1 FY26

related to respiratory illness, resulting from a light flu season

Mitigation:good underlying growth

Lower average selling prices for digital equipment Q1 FY26

due to continued softness in sales of Interroll scanners and treat printers... from new market entrants

Mitigation:higher sales volume (partially offsetting), opportunity to sell additional digital equipment to those customers going forward

Lower gross margin in Global Specialty Products Group Q1 FY26

due to sales mix of value to premium implants

Mitigation:expect to achieve improved growth in the Specialty Products Group going forward this year

Rising oil prices impacting freight costs and product pricing Q2 FY26 and beyond

anticipated further merchandise price increases in the second quarter

Mitigation:implemented a number of measures designed to offset the potential financial impact, working closely with our customers, not just defaulting to increasing prices or looking at fuel surcharges but there are some things that -- some measures we're trying to take to try to protect the margins

What to watch in Q2 FY26

Value creation benefits on G&A

second quarter and then even more so in the third and the fourth quarter
Current relatively nominal
Target accelerate

Why it matters

Expected to largely drive better earnings in the back half of the year.

the financial impact, at least with reference to the G&A portion of this was, I would say, was relatively nominal in the first quarter because we incurred some costs associated with the programs. We saved some costs associated with the program. we're going to start seeing that savings begin to accelerate as we get into the second quarter and then even more so in the third and the fourth quarter.

Find out whether HSIC delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked about the drivers of Q1 gross margin expansion, if value creation benefits are already showing, and how rising oil prices (freight/COGS) are being mitigated, including guidance assumptions for oil.

Ron South attributed gross margin improvement to early value creation benefits (dynamic pricing, own brand growth), strategic benefits, and supplier collaboration. He noted they are watching crude oil prices, taking measures to protect margins, and currently believe they can mitigate cost increases, with guidance assuming this mitigation.

“we are able to mitigate any related cost increases.”

asked by Jason Bednar · answered by Ronald South

2 min read 6 chapters

Detailed narrative

CEO's Strategic Vision and 100-Day Plan

New CEO Fred Lowery highlighted Henry Schein's competitive advantages, including its global reach, extensive integrated offering (BOLD+1 strategy), and excellent customer experience. His 100-day plan focuses on sharpening operational execution, building a stronger performance culture, and creating a leaner, more agile company to accelerate growth and improve financial results. He emphasized building continuous improvement processes rather than episodic cost-cutting.

Market Dynamics and Customer Needs

The dental market remains healthy with demand outpacing supply, driving customer needs for efficiency and workflow optimization. The medical market is shifting to nonacute care settings, aligning with Henry Schein's capabilities. Suppliers view Henry Schein as a key partner for growth due to deep customer access and trusted relationships, creating value through exclusive and targeted promotional programs.

Value Creation Initiatives

The company is executing value creation initiatives expected to drive over $200 million in annual operating income improvement, with a $125 million run rate by the end of 2026. Examples include outsourcing select back-office functions, strategically buying out minority partners to unlock integration opportunities, generating savings from indirect procurement, and implementing gross profit initiatives like value pricing and enhanced growth of corporate brands.

Technology and AI Solutions

Henry Schein is enhancing new product and service offerings, particularly in AI solutions, which are transforming the industry. The company launched its next-generation AI clinical workflow at the Thrive Live event, generating significant excitement and indicating customer readiness to embrace these tools. Cloud-based practice management software (Dentrix Ascend, Dentally) continues to see strong growth, with subscribers increasing 25% YoY to over 13,000.

E-commerce Platform Rollout

The global e-commerce platform, henryschein.com, has been successfully rolled out to Canadian and U.S. laboratory customers. Over 80% of U.S. dental e-commerce sales now transact through this platform, with full U.S. rollout expected by the end of August. Following the U.S. completion, the company plans to shift its focus to broader international deployment.

Capital Deployment and Cash Flow

During Q1 FY26, Henry Schein repurchased 1.6 million shares for $125 million at an average price of $77.64. Approximately $655 million remains authorized and available for future share repurchases. Operating cash flow was negative $97 million in Q1 due to normal seasonal decreases in accounts payable and accrued expenses, but is expected to exceed net income for the full year.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.